Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception
NCT06727734 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 980
Last updated 2026-05-14
Summary
The goal of this clinical trial is to compare the failure rate of the levonorgestrel (LNG)-piroxicam combination regimen versus ulipristal acetate (UPA) as emergency contraception (EC). The main questions it aims to answer are:
1. whether the LNG-piroxicam combination regimen has a lower failure rate than UPA for EC;
2. whether the LNG-piroxicam combination regimen has a higher percentage of pregnancies prevented than UPA for EC
3. whether there is any difference in the change in the subsequent menstrual cycle and adverse effect profile between the two regimens
Participants will:
1. Take a single dose of either (i) LNG 1.5 mg plus piroxicam 40 mg and a placebo tablet resembling UPA, or (ii) UPA 30 mg plus placebo tablets resembling LNG and piroxicam.
2. Have a blood test for serum LH, oestradiol an progesterone.
3. Keep a diary of their vaginal bleeding episodes, adverse effects symptoms, any further acts of intercourse and the type of contraception used.
4. Have a follow-up either in person by phone about 1-2 weeks after the next expected menstruation.
5. If normal menstrual bleeding has not occurred by that time, a pregnancy test will be carried out.
Conditions
- Contraception
Interventions
- DRUG
-
Levonorgestrel
Levonorgestrel 1.5 mg
- DRUG
-
Piroxicam
Piroxicam 40 mg
- DRUG
-
Ulipristal Acetate
Ulipristal 30 mg
- DRUG
-
Placebo - LNG
Placebo of levonorgestrel
- DRUG
-
Placebo - Piroxicam
Placebo of piroxicam
- DRUG
-
Placebo - UPA
Placebo of ulipristal acetate
Sponsors & Collaborators
-
The Family Planning Association of Hong Kong
collaborator OTHER -
The University of Hong Kong
lead OTHER
Principal Investigators
-
Raymond Hang Wun Li, MD, FRCOG · The University of Hong Kong
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-01-18
- Primary Completion
- 2027-09-30
- Completion
- 2027-10-31
Countries
- Hong Kong
Study Locations
More Related Trials
-
EC PK in Women With Normal and Obese BMI
NCT02689804 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
NCT02021097 ·Status: UNKNOWN ·Phase: PHASE3
-
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
NCT05444582 ·Status: RECRUITING ·Phase: PHASE4
-
Advance Supply of Emergency Contraception Compared to Routine Postpartum Care in Teens
NCT00433004 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Trial of CDB 2914 for Emergency Contraception
NCT00271583 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder
NCT00128934 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)
NCT02616146 ·Status: TERMINATED ·Phase: PHASE3
-
Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding
NCT07229209 ·Status: COMPLETED ·Phase: NA
-
Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.
NCT01569113 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days
NCT01953679 ·Status: COMPLETED ·Phase: PHASE2
-
Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period
NCT01088178 ·Status: WITHDRAWN ·Phase: NA
-
Same Day Oral EC and Implant Initiation
NCT04678817 ·Status: COMPLETED
-
Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women
NCT02403401 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
NCT00245921 ·Status: COMPLETED ·Phase: PHASE3
-
GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China
NCT00884260 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS
NCT00161681 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception
NCT00248963 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive
NCT03296098 ·Status: WITHDRAWN ·Phase: PHASE2
-
Stopping Heavy Periods Project
NCT02002260 ·Status: UNKNOWN ·Phase: NA
-
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
NCT07272889 ·Status: COMPLETED ·Phase: PHASE1
-
Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia
NCT03992937 ·Status: COMPLETED ·Phase: NA
-
The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception
NCT00966771 ·Status: COMPLETED
-
Copper T380 IUD Versus Oral Levonorgestrel for Emergency Contraception vs. Plan B for Emergency Contraception
NCT00669396 ·Status: COMPLETED ·Phase: NA
-
Ovarian Function With ENG Implant and UPA Use
NCT04291001 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception
NCT00551616 ·Status: COMPLETED ·Phase: PHASE3